Primary Application
For what
Blood and Cardiovascular
Immune and Lymphatic
Integumentary
Mitochondrial and Energy Production
Source
Allopathy
For whom
People
All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Similar ICs
309
41.8 k
10
604
166
56.8 k
180
110 k
10
456
385
51.4 k
472
136 k
120
35.9 k
165
54.5 k
450
77.4 k
Please select language
Select